Shinva Medical Instrument Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	9,419	9,864	9,904	9,072	9,343	8,994
Other Revenue	156.13	156.13	108	210.16	139.3	156.93
Revenue	9,575	10,021	10,012	9,282	9,482	9,151
Revenue Growth (YoY)	-5.37%	0.09%	7.87%	-2.11%	3.62%	4.38%
Cost of Revenue	7,217	7,461	7,394	6,863	7,200	7,088
Gross Profit	2,358	2,559	2,618	2,419	2,282	2,063
Selling, General & Admin	1,247	1,291	1,344	1,349	1,324	1,300
Research & Development	460.69	436.08	443.37	401.27	295.98	197.53
Other Operating Expenses	66.25	68.78	76.99	67.62	59.36	13.13
Operating Expenses	1,838	1,865	1,948	1,846	1,714	1,593
Operating Income	519.62	694.8	670.31	572.27	567.33	470.58
Interest Expense	-42.75	-44.79	-47.07	-56.93	-76.26	-121.45
Interest & Investment Income	84.91	95.57	110.96	61.75	126.94	58.98
Currency Exchange Gain (Loss)	4.14	4.14	7.54	10.37	-0.99	-5.48
Other Non Operating Income (Expenses)	-23.44	-21.91	-9.44	-4.17	-12.03	-24.24
EBT Excluding Unusual Items	542.48	727.8	732.3	583.29	604.99	378.39
Impairment of Goodwill	-15.22	-15.22	-11.49	-	-	-21.67
Gain (Loss) on Sale of Investments	-	-	12.54	-57.21	60.71	-0.17
Gain (Loss) on Sale of Assets	-2.6	-1.51	4.4	0.48	-0.35	-3.73
Asset Writedown	-19.31	-	-0.73	-	-0.62	-
Legal Settlements	-	-	-	-	-0.57	-10.65
Other Unusual Items	84.7	84.59	1.57	49.53	53.87	3.13
Pretax Income	590.04	795.66	738.58	576.09	718.03	345.3
Income Tax Expense	88.01	103.76	62.08	49.18	162.01	105.9
Earnings From Continuing Operations	502.03	691.9	676.5	526.91	556.02	239.4
Minority Interest in Earnings	6.89	-0.29	-22.5	-26.84	0.47	-5.26
Net Income	508.92	691.61	654	500.07	556.49	234.14
Net Income to Common	508.92	691.61	654	500.07	556.49	234.14
Net Income Growth	-26.49%	5.75%	30.78%	-10.14%	137.68%	-72.82%
Shares Outstanding (Basic)	664	607	595	529	528	525
Shares Outstanding (Diluted)	664	607	600	529	528	525
Shares Change (YoY)	18.89%	1.11%	13.53%	0.08%	0.64%	-0.65%
EPS (Basic)	0.77	1.14	1.10	0.95	1.05	0.45
EPS (Diluted)	0.77	1.14	1.09	0.95	1.05	0.45
EPS Growth	-38.17%	4.59%	15.20%	-10.21%	136.17%	-72.64%
Free Cash Flow	262.07	29.85	494.34	140.47	1,128	906.78
Free Cash Flow Per Share	0.40	0.05	0.82	0.27	2.14	1.73
Dividend Per Share	0.500	0.250	0.385	0.115	0.115	0.077
Dividend Growth	30.00%	-35.00%	233.28%	-	50.07%	-
Gross Margin	24.63%	25.54%	26.15%	26.06%	24.06%	22.55%
Operating Margin	5.43%	6.93%	6.69%	6.17%	5.98%	5.14%
Profit Margin	5.32%	6.90%	6.53%	5.39%	5.87%	2.56%
Free Cash Flow Margin	2.74%	0.30%	4.94%	1.51%	11.90%	9.91%
EBITDA	704.56	880.63	857.33	761.5	744.07	649.17
EBITDA Margin	7.36%	8.79%	8.56%	8.20%	7.85%	7.09%
D&A For EBITDA	184.94	185.84	187.03	189.23	176.74	178.6
EBIT	519.62	694.8	670.31	572.27	567.33	470.58
EBIT Margin	5.43%	6.93%	6.69%	6.17%	5.98%	5.14%
Effective Tax Rate	14.92%	13.04%	8.40%	8.54%	22.56%	30.67%
Revenue as Reported	9,575	10,021	10,012	9,282	9,482	9,151
Advertising Expenses	-	20.65	24.19	22.66	38.05	31.12

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.